# Profoundd archive — Epstein Files
# Bates number: EFTA02180090
# Title:        Sent Wed 11/9/2011 11:12:59 PM
# Dataset:      10
# Pages:        157
# Images:       157 detected
# Tags:         epstein, doj, dataset-10, image-described
# Source PDF:   https://profoundd.com/epstein-docs/EFTA02180090/download
# Doc viewer:   https://profoundd.com/epstein-docs/EFTA02180090
#
# Text below is what Profoundd has extracted from the source PDF.
# 'ocr-enriched' tag means OCR was applied to scan-only pages.
# Image descriptions are AI-generated factual captions (llava:13b).
#----------------------------------------------------------------------

=== SUMMARY ===
To: From: Sent Wed 11/9/2011 11:12:59 PM Subject Re: Ivory Coast CDC Health Information It looks pretty thorough to me! On Nov 9, 2011, at 6:11 PM,I wrote: I did. Do you think it's what he wants? I was a bit scared of him today !! Sent from my iPhone On Nov 9, 2011, at 5:43 PM, a wrote: thanks.. did you send this to JE as well? On Nov 9, 2011, at 3:21 PM, ivrote: e p a ri g f n r ri t p C 0 t e d' EF TA_R 1_00869348 EFTA02180090 Iv of r e B of or e vi si ti n 9 C at e di Iv of re y 0 ILI m ay n


=== EXTRACTED TEXT ===
To: 
From: 
Sent Wed 11/9/2011 11:12:59 PM 
Subject Re: Ivory Coast CDC Health Information 
It looks pretty thorough to me! 
On Nov 9, 2011, at 6:11 PM,I wrote: 
I did. Do you think it's what he wants? I was a bit scared of him today !! 
Sent from my iPhone 
On Nov 9, 2011, at 5:43 PM, a wrote: 
thanks.. did you send this to JE as well? 
On Nov 9, 2011, at 3:21 PM, ivrote: 
e 
p 
a 
ri 
g 
f n 
r 
ri 
t p 
C 
0 
t 
e 
d' 
EF TA_R 1_00869348 
EFTA02180090
Iv 
of 
r 
e 
B 
of 
or 
e 
vi 
si 
ti 
n 
9 
C 
at 
e 
di 
Iv 
of 
re 
y 
0 
ILI 
m 
ay 
n 
e 
e 
d 
to 
9 
et 
th 
e 
fo 
II 
0 
wi 
n 
9 
V3 
CC 
in 
at 
lo 
n 
s 
a 
n 
d 
m 
e 
di 
ca 
EFTA_R1_00869349 
EFTA02180091
ti 
n 
fo 
va 
cc 
in 
e-
pr 
ev 
nt 
a 
bl 
di 
se 
as 
es 
a 
n 
d 
of 
h 
er 
di 
se 
as 
es 
0 
m 
ig 
ht 
b 
at 
ri 
sk 
fo 
at 
0 
Ur 
d 
es 
ti 
n 
at 
io 
n: 
N 
EFTA_R1_00869350 
EFTA02180092
of 
Yo 
ur 
do 
Ct
or 
or 
he 
alt 
h-
ca 
re 
pr 
ov 
id 
er 
wi 
de 
to 
r 
mi 
ne 
w 
ha 
t 
y0 
wi 
ne 
ed 
de 
pe 
nd 
in 
9 
on 
fa 
Ct 
or 
su 
Ch 
as 
yo 
ur 
he 
alt 
h 
an 
d 
im 
un 
EFTA_R1_00869351 
EFTA02180093
iz 
ati 
on 
hi 
st 
Or 
Y. 
ar 
ea 
$ 
of 
th 
e 
co 
un 
tr 
y0 
1/0 
be 
vi 
sit 
in 
9, 
an 
PI 
an 
ne 
0 
ac 
tiv 
iti 
es 
.) 
To 
ha 
ye 
th 
e 
m 
os 
t 
be 
ne 
fit 
se 
e 
he 
alt 
h-
ca 
EFTA_R1_00869352 
EFTA02180094
re 
pr 
ov 
id 
er 
at 
le 
as 
t 
4-
6 
w 
ee 
ks 
be 
fo 
re 
yo 
tar 
tn 
p 
to 
all 
0 
w 
ti 
m 
e 
fo 
r 
yo 
Ur 
va 
CCi 
ne 
s 
to 
ta 
ke 
of 
fe 
ct 
an 
0 
to 
st 
ar 
t 
ta 
ki 
ng 
m 
ed 
ici 
ne 
to 
pr 
EFTA_R1_00869353 
EFTA02180095
ev 
en 
t 
m 
al 
art 
a, 
if 
yo 
ne 
ed 
it. 
Ev 
en 
if 
yo 
ha 
ve 
le 
ss 
th 
an 
4 
ve 
ee 
ks 
be 
fo 
re 
yo 
le 
av 
e, 
yo 
sh 
ou 
Id 
sb 
se 
e 
he 
alt 
h-
ca 
re 
pr 
ov 
id 
er 
fo 
EFTA_R1_00869354 
EFTA02180096
r 
ne 
ed 
ed 
va 
cci 
ne 
Si
an 
ti-
m 
al 
ari 
a 
dr 
ug 
$ 
an 
d 
ot 
he 
r 
m 
ed 
is 
ati 
on 
$ 
an 
a 
inf 
or 
m 
ati 
on 
ab 
ou 
ho 
w 
to 
pr 
ot 
ec 
yo 
ur 
se 
If 
fr 
O 
m 
it 
ne 
ss 
an 
d 
EFTA_R1_00869355 
EFTA02180097
inj 
ur 
w 
hil 
e 
tr 
av 
eli 
ng 
C 
D 
C 
re 
co 
m 
m 
en 
ds 
th 
at 
yo 
se 
e 
he 
alt 
h-
ca 
re 
pr 
ov 
id 
er 
w 
ho 
sp 
ec 
ial 
iz 
es 
in 
Tr 
av 
el 
M 
ed 
ici 
ne 
Li 
EEL 
B_ 
tE 
EFTA_R1_008693543 
EFTA02180098
m
1i
ne 
ni 
c 
ne 
ar 
yo 
u. 
If 
yo 
ha 
ye 
a 
m 
ed 
is 
al 
co 
nd 
iti 
on 
yo 
sh 
ou 
Id 
al 
so 
sh 
ar 
e 
yo 
ur 
tr 
av 
el 
pl 
an 
wi 
th 
an 
y 
do 
a 
or 
yo 
ar 
EFTA_R1_00869357 
EFTA02180099
e 
cu 
rr 
en 
tly 
se 
ei 
ng 
fo 
r 
of 
he 
r 
ed 
ic 
al 
re 
as 
on 
s. 
If 
yo 
ur 
tr 
av 
el 
PI 
an 
wi 
I 
to 
ke 
yo 
to 
or 
e 
th 
an 
on 
e 
co 
un 
tr 
du 
ri 
ng 
a 
si 
ng 
le 
tri 
EFTA_R1_00869358 
EFTA02180100
p. 
be 
su 
re 
to 
let 
y0 
ur 
he 
alt 
h-
Ca 
re 
pr 
ov 
id 
er 
kn 
O 
w 
so 
th 
at 
yo 
ca 
n 
re 
ce 
iv 
e 
th 
e 
ap 
pr 
op 
ria 
to 
va 
cci 
na 
do 
ns 
an 
d 
inf 
or 
m 
ati 
on 
fo 
r 
all 
of 
yo 
ur 
de 
EFTA_R1_00869359 
EFTA02180101
sti 
na 
do 
ns 
LO 
119-
te 
r 
m 
tr 
av 
el 
er 
s, 
su 
ch 
as 
th 
os 
e 
w 
ho 
pl 
an 
to 
w 
Or 
k 
or 
st 
ud 
y 
ab 
r0 
ad 
m 
ay 
al 
so 
ne 
ed 
ad 
dit 
io 
na 
va 
cci 
na 
do 
ns 
as 
re 
qu 
ire 
EFTA_R1_00869360 
EFTA02180102
d 
by 
th 
eir 
e 
m 
pi 
oy 
er 
Or 
Sc 
ho 
ol. 
B 
e 
$ 
ur 
y 
0 
ur 
ro 
ut 
in 
va 
cc 
in 
at 
io 
n 
ar 
p-
to-
d 
at 
e. 
C 
h 
ec 
k 
th 
i 
n 
ks 
b 
el 
0 
w 
to 
se 
EFTA_R1_00869361 
EFTA02180103
w 
hi 
ch 
va 
cc 
in 
at 
io 
n 
s 
a 
d 
Ili 
is 
a 
n 
d 
ch 
Il 
dr 
e 
n 
s 
h 
0 
ul 
d 
9 
et 
R 
0 
ut 
in 
e 
va 
cc 
in 
es 
as 
th 
ey 
ar 
e 
of 
to 
n 
Ca 
Ile 
0, 
su 
ch 
as 
fo 
r 
EFTA_R1_00869362 
EFTA02180104
inf 
lu 
en 
2,3 
Ch 
ic 
ke 
np 
ox 
(o 
r 
va 
nc 
ell 
a) 
po 
lio 
m 
ea 
sl 
es 
m 
m 
ps 
/r 
ub 
ell 
a 
(hi 
M 
R) 
an 
d 
di 
ph 
th 
en 
a/ 
pe 
rt 
us 
sis 
/t 
et 
an 
us 
(D 
PT 
ar 
e 
E FTA_R 1_00869363 
EFTA02180105
gi 
ve 
n 
at 
all 
st 
ag 
es 
of 
hf 
e; 
se 
e 
th 
e 
Sh 
fig 
ha 
SOL 
St 
ag 
ce
1PLI 
MO 
iz 
cat 
411 
14 
an 
d 
rs 
liti 
mit 
im 
ID
sin 
iz 
asi 
he 
sist 
le• 
RO 
uti 
ne 
EFTA_R1_00869364 
EFTA02180106
va 
cci 
ne 
a r 
e 
re 
co 
in 
in
en 
de 
d 
ev 
en 
if 
yo 
do 
no 
t 
tr 
av 
el. 
Al 
th 
ou 
gh 
Ch 
ild 
ho 
od 
di 
se 
as 
es 
su 
Ch 
as 
ea 
sl 
es 
ra 
rel 
oc 
cu 
r 
in 
th 
e 
nit 
ed 
EFTA_R1_00869365 
EFTA02180107
St 
at 
es 
th 
ey 
ar 
e 
sti 
I 
co 
m 
m 
on 
in 
m 
an 
pa 
rt 
of 
th 
e 
w 
orl 
d. 
tr 
av 
el 
er 
w 
ho 
is 
no 
va 
cci 
na 
to 
d 
w 
ou 
Id 
be 
at 
ris 
k 
fo 
r 
inf 
ec 
tio 
n. 
V 
EFTA_R1_00869366 
EFTA02180108
rr a- M 0 CL fD fa/ 0' fD aim 3 3 2, mz < LA (I) Lei CLI rD iron  OCD cr rt.= (1) < N -% -O? z n n 
m 
Ix 
0 8 
EFTA02180109
co 
8 0 0 
w 
> to .3 4) -ti -I% .t 2 E coca al 4.1 c ar5 -Ewa) > "6 t ° > 'vc iv' w >ivt'm arcl wn.5ducutmc rnw.a
EFTA02180110
a 
n 
y 
tl 
m 
e. 
Vaccination or 
Disease 
ROutme Recommendations or 
Requirements for Vaccine-
Preventable Diseases 
Recommended if you are not up-to-date 
with routine shots, such as 
measles/mumps/rubella (MMR) vaccine, 
diphtheria/pertussis/tetanus (OPT) 
vaccine, poliovirus vaccine, etc. 
Hepatitis A or Recommended for all unvaccinated 
immune people traveling to or working in 
globulin (IG) countries with an intermediate or high 
level of hepatitis A virus infection (at 
mao) where exposure might occur 
through food or water. Cases of travel-
: related hepatitis A can also occur in 
travelers to developing countries with 
"standard" tourist itineraries, 
accommodations, and food consumption 
behaviors. 
Hepatitis B Recommended for all unvaccinated 
persons traveling to or working in 
countries with intermediate to high levels 
of endemic HBV transmission (see map, 
especially those who might be exposed 
to blood or body fluids, have sexual 
contact with the local population, or be 
exposed through medical treatment 
(e.g., for an accident). 
Tvohoig 
POO Recommended for all unvaccinated 
people traveling to or working in West 
Africa, especially if staying with 
friends or relatives or visiting smaller 
cities, villages, or rural areas where 
exposure might occur through food or 
water. 
Recommended for adult travelers who 
have received a primary series with 
either inactivated poliovirus vaccine 
(IPV) or oral polio vaccine (OPV). They 
should receive another dose of IPV 
before departure. For adults, available 
data do not indicate the need for more 
than a single lifetime booster dose with 
WV. 
EFTA_R1_00869389 
EFTA02180111
Yellow Fever Requirements: Required upon arrival 
from all countries for travelers 21 year 
of age. 
Recommendations: Recommended fo 
r all travelers 29 months of age. 
Vaccination should be given 10 days 
before travel and at 10-year intervals if 
there is on-going risk. Find an authorized 
U.S. yellow fever vaccination clinic. 
Meninaococcal 
(meningitis) Recommended If you plan to visit 
countries that experience epidemics of 
meningococcal disease during December 
through June (see map). 
Rabies 
M 
at 
a 
ri 
a Recommended for travelers spending 
a lot of time outdoors, especially in 
rural areas, involved in activities such 
as bicycling, camping, or hiking. Also 
recommended for travelers with 
significant occupational risks (such as 
veterinarians), for long-term travelers 
and expatriates living in areas with a 
significant risk of exposure, and for 
travelers involved in any activities 
that might bring them into direct 
contact with bats, carnivores, and 
other mammals. Children are 
considered at higher risk because 
they tend to play with animals, may 
receive more severe bites, or may not 
report bites. 
EFTA_R1_00869370 
EFTA02180112
EFTA_R1_00869371 
EFTA02180113
Ir
iy 
0 
iv 
ti 
tg 
ly 
0 
In 
CI 
uc: 
e 
th 
fol 
lo 
ng 
EFTA_R1_00869372 
EFTA02180114
EFTA_R1_00869373 
EFTA02180115
EFTA_R1_00869374 
EFTA02180116
EFTA_R1_00869375 
EFTA02180117
9 
eq 
op 
10 
fls 
0 
pr 
ev 
en 
in 
1,1 
Coal
ar 
a 
to 
vo 
ire 
A 
to 
qu 
on 
pr 
09 
lid 
ml 
do 
xy 
cy 
Cli 
ne 
or 
m 
efI 
oq 
LJI 
ne 
or 
de 
tal 
EFTA_R1_00869376 
EFTA02180118
EFTA_R1_00869377 
EFTA02180119
e 
0 
it 
to 
t 
Ir 
le 
le 
if 
h 
9 
Id 
be 
be 
St 
fo 
r 
yo 
u. 
Pt 
ea 
se 
se 
EFTA_ R1_ 00869378 
EFTA02180120
N 
of 
C 
hl 
or 
0 
ui 
n 
is 
N 
O 
T 
a 
n 
of 
fe 
Ct 
iv 
a 
nt 
m 
al 
ar 
is 
d 
9 
in 
C 
of 
Iv 
re 
a 
n 
d 
h 
0 
ul 
b of 
k 
EFTA_ R1_ 00869379 
EFTA02180121
to 
pr 
cv 
nt 
m 
al 
ar 
is 
in 
th 
is 
re 
InO
n 
ah 
On 
tl 
1'0 
ug 
ho 
th 
yo ut
us 
Ill 
EFTA_R1_00869380 
EFTA02180122
EFTA_R1_00869381 
EFTA02180123
ati 
on 
an 
d 
th 
e 
re 
co 
m 
m 
en 
de 
d 
Pr 
ev 
en 
to 
m 
ed 
ici 
ne 
$ 
fo 
r 
th 
at 
ar 
ea 
al 
ar 
is 
C 
0 
nt 
ac 
t 
to 
H 
e 
al 
th-
C 
ar 
Pr 
0 
vi 
d 
er 
For assistance with the diagnosis or management of 
SU 
EFTA_R1_00869382 
EFTA02180124
sp 
ec 
to 
ca 
se 
of 
m 
al 
ari 
a, 
ca 
I 
th 
e 
C 
D 
C 
M 
al 
an 
a 
H 
otl 
in 
e: 
77 
0-
48 
8-
77 
88 
(M-
F, 
9 
a 
m-
5 
p 
m 
Ea 
st 
er 
n 
ti 
m 
e) 
FO 
r 
e 
m 
er 
ge 
nc 
EFTA_R1_00869383 
EFTA02180125
co 
ns 
ult 
ati 
on 
of 
to 
r 
ho 
ur 
s, 
ca 
77 
0-
48 
8-
71 
00 
an 
as 
k 
to 
sp 
ea 
k 
wi 
th 
a 
C 
D 
C 
al 
ari 
a 
Br 
an 
Ch 
Cli 
ni 
Ci 
an 
A 
S 
p 
ec 
is 
N 
of 
e 
EFTA_R1_00869384 
EFTA02180126
b 
0 
ut 
A 
nt 
m 
al 
ar 
is 
Dr 
gs 
YID 
sh 
ou 
Id 
pu 
rC 
ha 
se 
yo 
ur 
an 
ti 
m 
al 
ari 
at 
dr 
ug 
$ 
be 
fo 
re 
tr 
av 
el. 
Dr 
ug 
$ 
pu 
rC 
ha 
se 
d 
ov 
er 
se 
as 
m 
ay 
no 
t 
EFTA_R1_00869385 
EFTA02180127
be 
m 
an 
of 
ac 
to 
re 
d 
ac 
co 
rd 
in 
9 
to 
nit 
ed 
St 
at 
es 
st 
an 
da 
rd 
an 
ay 
no 
be 
of 
fe 
cti 
ye 
Th 
ey 
al 
so 
ay 
be 
da 
ng 
er 
ou 
s, 
co 
nt 
ai 
n 
co 
un 
to 
rf 
EFTA_R1_00869386 
EFTA02180128
eit 
m 
ed 
ic 
ati 
on 
or 
co 
nt 
a 
mi 
na 
nt 
s, 
or 
be 
co 
m 
bi 
na 
do 
ns 
of 
or 
ug 
th 
at 
ar 
e 
no 
t 
sa 
fe 
to 
us 
e. 
H 
al 
of 
an 
tri 
ne 
m 
ar 
ke 
to 
as 
H 
alf 
an 
is 
EFTA_R1_00869387 
EFTA02180129
wi 
de 
ly 
us 
ed 
ov 
er 
se 
as 
to 
tr 
ea 
t 
m 
al 
ari 
a. 
C 
D 
C 
re 
co 
m 
m 
en 
ds 
th 
at 
y0 
do 
N 
T 
us 
e 
ha 
lof 
an 
tri 
ne 
be 
ca 
us 
e 
of 
se 
rio 
us 
he 
ar 
t-
rel 
at 
ed 
si 
de 
EFTA_R1_00869388 
EFTA02180130
of 
fe 
Ct 
s, 
in 
CI 
ud 
in 
de 
at 
hs 
Yo 
sh 
ou 
Id 
av 
Oi 
d 
us 
in 
an 
ti 
m 
al 
an 
al 
dr 
ug 
$ 
th 
at 
ar 
e 
no 
t 
re 
co 
m 
m 
en 
de 
d 
nl 
es 
yo 
ha 
ye 
be 
en 
di 
EFTA_R1_00869389 
EFTA02180131
ag 
no 
se 
d 
wi 
th 
lif 
e-
th 
re 
at 
en 
in 
9 
m 
al 
ari 
a 
an 
no 
of 
he 
r 
op 
tio 
ns 
3r 
e 
im 
m 
ed 
iat 
el 
V 
av 
ail 
ab 
le. 
FO 
r 
de 
tai 
le 
int 
or 
m 
ati 
on 
ab 
ou 
th 
es 
e 
EFTA_R1_00869390 
EFTA02180132
an 
tl 
al 
an 
al 
0r 
ug 
s, 
se 
a 
bs 
in 
Mt
le_ 
gn 
ari 
a• 
M 
r 
e 
In 
fo 
r 
m 
at 
io 
n 
b 
0 
t 
M 
al 
a 
ri 
a 
14 
al 
ar 
EFTA_R1_00869391 
EFTA02180133
la 
is 
al 
w 
ay 
s 
a 
se 
rio 
us 
di 
se 
as 
e 
an 
d 
m 
ay 
be 
a 
de 
ad 
ly 
ill 
ne 
ss 
H 
u 
m 
an 
s 
ge 
t 
rn 
al 
ari 
a 
fr 
0 
m 
th 
e 
bit 
e 
of 
a 
m 
os 
qu 
ito 
inf 
ec 
to 
d 
wi 
th 
EFTA_R1_00869392 
EFTA02180134
th 
e 
pa 
ra 
sit 
e. 
Pr 
ev 
en 
t 
thi 
se 
rio 
us 
di 
se 
as 
e 
by 
se 
ei 
ng 
yo 
ur 
he 
alt 
h-
Ca 
re 
pr 
ov 
id 
er 
fo 
r 
pr 
es 
cri 
pti 
on 
an 
ti 
al 
an 
al 
dr 
ug 
an 
d 
by 
pr 
of 
ec 
tin 
EFTA_R1_00869393 
EFTA02180135
g 
yo 
ur 
se 
If 
ag 
ai 
ns 
m 
os 
qu 
ito 
bit 
es 
ee, 
kg 
LIO 
Tr 
av 
el 
er 
$ 
to 
al 
an 
ris 
k-
ar 
ea 
$ 
in 
C6 
to 
vo 
ire 
in 
CI 
ucl 
in 
9 
inf 
an 
ts, 
ch 
ilo 
re 
n, 
an 
EFTA_R1_00869394 
EFTA02180136
fo 
r 
m 
er 
re 
si 
de 
nt 
of 
Co 
te 
vo 
ire 
sh 
ou 
Id 
to 
Ice 
on 
e 
of 
th 
e 
an 
ti 
m 
al 
ari 
al 
Or 
ug 
lis 
te 
0 
in 
th 
e 
bo 
x 
ab 
ov 
e. 
$ 
m 
t 
0 
m 
5 
EFTA_R1_00869395 
EFTA02180137
M 
al 
an 
a 
sy 
m 
Pt 
0 
m 
s 
m 
ay 
in 
CI 
ud 
e 
• 
f 
e 
v 
e 
r 
• 
c 
h 
i 
1 
I 
s 
• 
s 
w 
e 
a 
t 
s 
• 
h 
e 
a 
d 
a 
c 
h 
e 
• 
b 
0 
d 
y 
a 
c 
EFTA_R1_00869396 
EFTA02180138
h 
e 
s 
• 
n 
a 
u 
s 
e 
a 
a 
n 
d 
v 
0 
m 
i 
t 
i 
n 
9 
• 
f 
a 
t 
I 
9 
u 
e 
M 
at 
ari 
a 
sy 
m 
pt 
0 
m 
s 
wi 
II 
of 
Cu 
r 
at 
le 
as 
t 
7 
to 
9 
da 
ys 
of 
to 
EFTA_R1_00869397 
EFTA02180139
r 
be 
in 
9 
bit 
te 
n 
by 
an 
Inf 
ec 
te 
m 
os 
qu 
ito 
Fe 
ye 
r 
in 
th 
e 
fir 
st 
w 
ee 
k 
of 
tr 
av 
el 
in 
a 
m 
al 
ari 
a-
ris 
k 
ar 
ea 
is 
un 
lik 
el 
y 
to 
be 
m 
al 
ari 
a; 
ho 
w 
ev 
EFTA_R1_00869398 
EFTA02180140
er 
yo 
sh 
ou 
Id 
se 
e 
do 
ct 
or 
ri 
gh 
t 
w 
ay 
if 
yo 
de 
ye 
lo 
a 
fe 
ye 
Cur
ri 
ng 
yo 
ur 
tri 
p. 
M 
al 
an 
m 
ay 
Ca 
US 
e 
an 
e 
mi 
a 
an 
C 
ja 
un 
Ci 
ce 
EFTA_R1_00869399 
EFTA02180141
M al 
an 
a 
inf 
ec 
do 
ns 
WI 
th 
PI 
as 
fil 
od 
iu 
fa/ 
ci 
pa 
ru 
if 
no 
t 
pr 
a 
m 
ptl 
tr 
ea 
to 
d, 
m 
ay 
ca 
us 
e 
ki 
do 
ey 
fai 
lu 
re 
co 
a, 
an 
d 
de 
at 
h. 
D 
es 
EFTA_R1_00869400 
EFTA02180142
pit 
e 
us 
in 
9 
th 
e 
pr 
of 
ec 
tiv 
e 
ea 
su 
re 
$ 
ou 
to 
ne 
ab 
ov 
e, 
tr 
av 
el 
er 
m 
ay 
sti 
de 
ye 
lo 
p 
m 
al 
ari 
a 
up 
to 
a 
ye 
ar 
of 
to 
r 
re 
to 
rn 
in 
9 
fr 
0 
m 
EFTA_R1_00869401 
EFTA02180143
a 
al 
all 
Cu 
$ 
ar 
ea 
Yo 
sh 
ou 
Id 
se 
e 
do 
ct 
or 
um 
m 
ed 
lat 
el 
y 
if 
yo 
de 
ye 
to 
a 
fe 
ye 
r 
an 
yti 
e 
du 
ri 
ng 
th 
e 
ye 
ar 
fol 
lo 
WI 
ng 
yo 
ur 
re 
to 
rn 
EFTA_R1_00869402 
EFTA02180144
an 
tel 
th 
e 
ph 
y5 
id 
an 
of 
yo 
ur 
tr 
av 
el. 
It 
e 
m 
t 
O 
B 
ri 
it 
h 
O 
e 
di 
ci 
n 
0 
m 
ay 
n 
e 
e 
d: 
T 
h 
EFTA_R1_00869403 
EFTA02180145
cc 0 Dm fr, < cu 7 c O.< cli -t c in i'D r tux • .< iv a< n8COMM CS "C 0 •C a ID 3 'el'CL al 3 3 0 0,13 --1 n b tint al 
lO
0 
2 0 a 
EFTA02180146
t 
0 h 
d 
r 
9 
0 
r 
r 
K 
e 
e 
t 
h 
e 
n 
t 
h 
e 
r 
0 
r t 
n 
r 
e 
r 
t 
0 
n 
b 
0 
EFTA_R1_00869405 
EFTA02180147
0.0 •-‹ •-•• — •-• c 0 et sn * O-- 0 -I• 0^ et -3 c 00 03 • MC CY 0 IC) C - 3 01 -1-1 CV O-I c 0 ••< z — III ••< te * — ft Cc 3 CV V/ Ci —
EFTA02180148
u 
i 
d 
e 
i 
n 
e 
s 
< 
i 
c 
0 
n 
0 
u 
t 
P 
n 
9 
> 
i 
f 
t 
h 
e 
m 
e 
d 
i 
c 
i 
n 
e 
s 
a 
r 
e 
i 
cl 
u 
i 
d 
$ 
• 
A 
n 
t 
i 
m 
a 
I 
a 
EFTA_R1_00869407 
EFTA02180149
r 
i 
a 
I 
d 
r 
u 
9 
s 
i 
f 
t 
r 
a 
v 
e 
i 
n 
9 
t 
0 
a 
m 
a 
a 
r 
i 
a-
r 
i 
s 
k 
a 
r 
e 
a 
i 
n 
C 
8 
t 
e 
d 
I 
v 
0 
i 
r 
e 
a 
n 
d 
P 
EFTA_R1_00869408 
EFTA02180150
e 
$ 
r 
b 
e 
d 
b 
0 
r 
d 
0 
t 
0 
r 
• 
M 
e 
d 
n 
e 
f 
0 
r 
d r 
r 
h 
e r 
a 
V 
e 0 
-
h t 
-
EFTA_R1_00869409 
EFTA02180151
C 
0 
U 
n 
t 
e 
r 
N 
ot 
e: 
So 
m 
e 
Er 
ug 
$ 
av 
ail 
ab 
le 
by 
pr 
es 
cri 
pti 
on 
in 
th 
e 
U 
S 
ar 
e 
it 
eg 
al 
in 
ot 
he 
r 
co 
un 
tri 
es 
C 
he 
ck 
th 
e 
U 
S 
D 
ep 
ar 
EFTA_R1_00869410 
EFTA02180152
m 
en 
of 
St 
at 
e 
cQ 
of 
19
ID
he
gt 
<i 
co 
n_ 
ou 
t. 
pn 
9 
fo 
r 
th 
e 
co 
un 
tr 
s) 
yo 
int 
en 
d 
to 
vi 
sit 
or 
th 
e 
e 
m 
ba 
ss 
or 
CO 
EFTA_R1_00869411 
EFTA02180153
ns 
ul 
at 
e 
fo 
r 
th 
at 
co 
un 
tr 
Y( 
5) 
If 
yo 
Ur 
m 
ad 
is 
ati 
on 
is 
no 
t 
all 
0 
w 
ed 
in 
th 
e 
co 
un 
tr 
yo 
U 
wi 
be 
vi 
sit 
in 
9, 
as 
k 
yo 
Ur 
he 
alt 
h-
ca 
re 
pr 
oy 
id 
EFTA_R1_00869412 
EFTA02180154
er 
to 
wr 
ite 
a 
let 
to 
r 
on 
of 
fiC 
e 
st 
ati 
on 
er 
st 
ati 
ng 
th 
e 
m 
ed 
ic 
ati 
on 
ha 
be 
en 
pr 
es 
Crl 
be 
d 
fo 
r 
yo 
u. 
Ot 
h 
er 
it 
m 
y 
0 
in 
ay 
n 
d: 
EFTA_R1_00869413 
EFTA02180155
N et r• O a CP O n "s (T) " CV CD " ", 0 -0 aD as wet ID —awry ID 7 a 0 •-• • 
m 
ID
i0 
EFTA02180156
w d 
e 
r 
$ 
n 
0 
t t 
V 
a 
e 
e e 
t e 
w 
e 
r 
F 
t 
e 
r t 
e 
t 
0 
C 
0 
m 
m 
EFTA_R1_00869415 
EFTA02180157
e 
r 
C 
a 
I 
I 
Y-
B 
0 
t 
t 
e 
d 
W 
a 
t 
e 
r 
a 
n 
d 
O 
t 
h 
e 
r 
B 
e 
v 
e 
r 
a 
9 
e 
s 
a 
n 
d 
S 
a 
f 
e 
F 
0 
o 
d 
a 
n 
d 
W 
a 
t 
e 
r 
EFTA_R1_00869416 
EFTA02180158
f 
0 
r 
m 
0 
r 
e 
d 
e 
t 
a 
i 
I 
e 
d 
i 
n 
f 
0 
r 
m 
a 
t 
i 
0 
n 
• 
S 
u 
n 
b 
0 
c 
k 
a 
n 
d 
s 
u 
n 
9 
a 
s 
s 
e 
s 
f 
0 
r 
P 
r 
0 
t 
e 
c 
EFTA_R1_00869417 
EFTA02180159
r 
O 
m O 
m 
f 
U 
e 
e 
t 
O 
U r 
U 
r S 
e 
e 
B S 
n 
0 
r 
m I 
0 
n 
b 
0 
U 
t 
EFTA_R1_00869418 
EFTA02180160
S 
k 
n 
C 
a 
n 
c 
e 
r 
f 
0 
r 
m 
0 
r 
e 
n 
f 
0 
r 
m 
a 
t 
0 
n 
A 
n 
t 
b 
a 
c 
t 
e 
r 
a 
I 
h 
a 
n 
d 
w 
P 
e 
s 
0 
r 
a 
c 
EFTA_R1_00869419 
EFTA02180161
h 
0 0 
a 
d 
h e 
d 
z 
e 
r 
0 
n 
t t 
9 
e t 
t 
0 
0/0 
a 
0 
h 
0 
• To prevent Insect/mosquito bites, bring: 
o Lightweight long-sleeved shirts, long pants, and 
a hat to wear outside, whenever possible. 
o Flying-Insect spray to help dear rooms of 
mosquitoes. The product should contain a 
pyrethrold insecticide; these Insecticides quickly kill 
flying Insects, Including mosquitoes. 
o Bed nets treated with permethrin, if you will not 
be sleeping In an air-conditioned or well-screened 
EFTA_R1_00869420 
EFTA02180162
room and will be in malaria-risk areas. For use and 
purchasing information, seelnsecticide Treated Bed 
Nets on the CDC malaria site. Overseas, permethrin 
or another insecticide, deltamethrin, may be 
purchased to treat bed nets and clothes. 
Se 
e 
ot 
he 
r 
su 
99 
es 
te 
d 
ov 
er-
th 
e-
co 
un 
te 
r 
m 
ed 
lc 
at, 
on 
an 
d 
fir 
st 
al 
d 
Ite 
m 
fo 
r 
tr 
av 
el 
er 
s' 
he 
alt 
h 
N 
ot 
e: 
C 
he 
EFTA_R1_00869421 
EFTA02180163
Ck 
th 
e 
Al 
r
Tr 
41. 
en 
<I 
CO 
n_ 
Cu 
t. 
pn 
9 
> 
of 
th 
e 
an 
SR 
9.r 
tie 
n_ 
Si 
Cu 
Lit 
y_ 
A 
mi 
Dl
It 
La 
tie 
<i 
co 
n_ 
ou 
t. 
pn 
9 
w 
eb 
sit 
e 
fo 
r 
th 
e 
EFTA_R1_00869422 
EFTA02180164
lat 
es 
t 
inf 
or 
m 
ati 
on 
ab 
ou 
t 
air 
po 
rt 
sc 
re 
en 
in 
9 
pr 
oc 
ed 
ur 
es 
an 
pr 
oh 
ibi 
to 
ite 
m 
s. 
To 
nf 
Pd 
0 
t 
h 
e 
r 
D 
is 
e 
e 
F 
EFTA_R 1_00869423 
EFTA02180165
O 
u 
n 
d 
in 
W 
e 
st 
A 
fr 
is 
a 
Risk can vary between countries within this region and 
at 
so 
wi 
th 
in 
a 
CO 
u 
nt 
ry
th 
e 
cl 
ua 
lit 
y 
of 
in-
co 
u 
nt 
ry 
su 
ry 
ei 
El 
an 
ce 
at 
so 
va 
ri 
es 
Th 
e 
fol 
lo 
vo 
ng 
E FTA_R 1_00869424 
EFTA02180166
ar 
e 
di 
se 
as 
e 
ris 
k$ 
th 
at 
mi 
gh 
of 
fe 
ct 
tr 
av 
el 
er 
s; 
thi 
$ 
is 
no 
a 
co 
m 
PI 
et 
e 
lis 
of 
di 
se 
as 
es 
th 
at 
ca 
n 
be 
pr 
es 
en 
t. 
En 
vir 
on 
m 
en 
tal 
co 
nd 
iti 
EFTA_R1_00869425 
EFTA02180167
on 
m 
ay 
al 
so 
Ch 
an 
ge 
an 
up 
to 
da 
to 
inf 
or 
m 
as 
on 
ab 
ou 
t 
ris 
k 
by 
re 
91
on 
wi 
thi 
a 
co 
un 
tr 
y 
m 
ay 
al 
so 
no 
t 
al 
w 
ay 
$ 
be 
av 
ail 
ab 
le. 
D 
en 
EFTA_R1_00869426 
EFTA02180168
2, 
fll 
is 
li 
m 
an 
Qn 
Qc 
ci 
is 
(ri 
ye 
r 
bli 
nO 
ne 
ss 
ar 
e 
of 
he 
r 
di 
se 
as 
es 
ca 
rri 
eci 
by 
in 
se 
ct 
th 
at 
al 
so 
oc 
Cu 
r 
in 
EFTA_R1_00869427 
EFTA02180169
es 
t At 
Ht 
a. 
A 
Id
CA 
Y.32 
Ali 
IL 
L 
fri 
Di 
act. 
ic
kL 
4,4 
sl 
h 
as 
in 
Cr 
ea 
se 
d in 
Af 
ric 
a 
(it 
is 
ep 
id 
e 
mi 
in 
A 
ng 
of 
a, 
D 
e 
m 
oc 
ra 
EFTA_R1_00869428 
EFTA02180170
tic 
Re 
pu 
bli 
C 
of 
th 
e 
Co 
ng 
o, 
an 
th 
e 
$ 
ucl 
an 
• 
an 
hi 
gh 
ly 
en 
de 
mi 
C 
in 
Ca 
m 
er 
00 
n, 
Ce 
In 
ral 
Af 
ric 
an 
Re 
pu 
bli 
C, 
C 
ha 
Co 
ng 
o, 
C8 
to 
crl 
vo 
ire 
G 
EFTA_R1_00869429 
EFTA02180171
ui 
ne 
a, 
oz 
a 
bi 
qu 
e, 
ga 
nd 
a, 
an 
d 
Ta 
nz 
an 
is 
io 
w 
le 
ve 
Is 
ar 
e 
fo 
un 
d 
in 
m 
os 
t 
of 
th 
e 
of 
he 
co 
un 
to 
es 
), 
an 
d 
an 
in 
Cr 
ea 
se 
in 
tr 
av 
el 
EFTA_R1_00869430 
EFTA02180172
er 
ha 
be 
en 
no 
to 
d 
si 
nc 
e 
20 
00 
os 
t 
ha 
d 
ex 
po 
su 
re 
in 
ia 
nz 
an 
a 
an 
d 
Ke 
ny 
a, 
re 
fle 
cti 
ng 
co 
m 
m 
on 
to 
ur 
ist 
ro 
ut 
es 
IF,t6PgRaP' 
EFTA_R1_00869431 
EFTA02180173
a 
If 
n.s 
in 
SL 
1t
w 
it 
he 
1p 
to 
Pr 
ev 
en 
th 
es 
e 
di 
se 
as 
es 
SS 
hi 
SS 
9$
ml 
is, 
a 
pa 
ra 
sit 
is 
inf 
ec 
tio 
n, 
ca 
be 
co 
rit 
ra 
ct 
ed 
in 
fr 
es 
EFTA_R1_00869432 
EFTA02180174
h 
w 
at 
er 
in 
thi 
re 
91
on 
D 
0 
no 
t 
$ 
wi 
m 
in 
fr 
es 
h 
w 
at 
er 
(e 
xc 
ep 
t 
in 
w 
ell-
ch 
lor 
in 
at 
ed 
$ 
wi 
m 
mi 
ng 
po 
01 
s) 
in 
th 
es 
e 
co 
un 
to 
es 
P9 
EFTA_R1_00869433 
EFTA02180175
ho 
0 
ut 
br 
ea 
ks 
yr 
er 
e 
re 
po 
rt 
ed 
in 
se 
ve 
ral 
pr 
ev 
io 
us 
ly 
po 
lio-
fr 
ee 
Co 
un 
trt 
es 
in 
Ce 
nt 
ral 
Ea 
st 
er 
n, 
an 
d 
es 
to 
rn 
Af 
riC 
be 
gi 
nn 
in 
9 
in 
20 
03 
EFTA_R1_00869434 
EFTA02180176
Po 
lio 
is 
sti 
II 
en 
de 
mi 
c 
in 
Ni 
ge 
ria 
Tr 
av 
el 
er 
s 
to 
ru 
ral 
ar 
ea 
s 
of 
w 
es 
t 
Af 
riC 
a 
m 
ay 
be 
ex 
po 
se 
d 
to 
I. 
Li 
sa 
Yir 
sil 
w 
hi 
ch 
is 
sp 
re 
ad 
th 
IV 
ug 
EFTA_R1_00869435 
EFTA02180177
h 
co 
nt 
ac 
wi 
th 
ra 
ur 
in 
e 
or 
Cr 
op 
pi 
ng 
s. 
Pe 
op 
le 
ca 
n 
be 
ex 
po 
se 
to 
La 
ss 
a 
vir 
us 
by 
in 
ha 
lin 
9 
tin 
y 
pa 
rti 
CI 
es 
of 
th 
es 
e 
ex 
Cr 
etl 
on 
in 
th 
e 
EFTA_R1_00869436 
EFTA02180178
air 
es 
pe 
ci 
all 
if 
th 
ey 
st 
ay 
in 
tr 
ad 
iti 
on 
al 
w 
ell 
in 
gs 
Tr 
av 
el 
er 
sh 
Cu 
Id 
av 
of 
co 
nt 
ac 
wi 
th 
ra 
is 
an 
d 
sh 
ou 
Id 
no 
st 
ay 
in 
d 
w 
ell 
in 
EFTA_R1_00869437 
EFTA02180179
gs 
th 
at 
m 
ay 
be 
inf 
es 
to 
d 
vn 
th 
To 
ts. 
H 
m 
an-
to-
hu 
an 
tr 
an 
mi 
ssi 
on 
of 
th 
e 
di 
se 
as 
e 
ha 
be 
en 
de 
Sc 
ri 
be 
d. 
12 
R5 
L 
EA 
17_ 
Pr
ALI 
$ DA 
EFTA_R1_00869438 
EFTA02180180
ho 
ul 
d 
be 
fol 
lo 
ed 
to 
pr 
ev 
en 
t 
hu 
m 
an-
to-
hu 
m 
an 
tr 
an 
mi 
ssi 
on 
fr 
O 
m 
inf 
ec 
to 
d 
pe 
op 
le. 
Hi 
gh 
ly 
pa 
th 
og 
en 
is 
av 
is 
n 
inf 
lu 
en 
za 
(H 
S 
N 
1) 
ha 
EFTA_R1_00869439 
EFTA02180181
be 
en 
fo 
un 
d 
in 
po 
ult 
ry
po 
pu 
lat 
io 
ns 
in 
se 
ye 
ral 
to 
un 
to 
es 
in 
Af 
riC 
a. 
Av 
di 
d 
all 
di 
re 
a 
co 
nt 
ac 
t 
wi 
th 
bi 
rd 
s, 
in 
Cl 
u0 
in 
9 
do 
m 
es 
tic 
po 
ult 
ry
(a 
uc 
EFTA_R1_00869440 
EFTA02180182
h 
as 
ch 
IC 
Ice 
ns 
an 
a 
du 
ck 
s) 
an 
wi 
Id 
bi 
rd 
s, 
an 
av 
oi 
pi 
aC 
es 
su 
ch 
as 
p0 
ult 
ry
fa 
r 
an 
a 
bi 
rd 
m 
ar 
ke 
is 
w 
he 
re 
liv 
e 
bi 
rd 
5 
ar 
e 
rai 
se 
EFTA_R1_00869441 
EFTA02180183
or 
ke 
Pt 
FO 
r 
Cu 
rr 
en 
'Is 
of 
co 
un 
to 
es 
re 
po 
rti 
ng 
ou 
tb 
re 
ak 
of 
H 
N 
a 
m 
on 
9 
po 
ult 
ry
an 
or 
vn 
Id 
bi 
rd 
5, 
vi 
e 
w 
YR 
9s1 
If
52 
Q 
EFTA_R1_00869442 
EFTA02180184
In 
I 
gti 
Qr 
gd 
Di 
fq
L is 
Di 
ea 
H
DL) 
(Q 
ic 
on 
O 
ut 
.p 
ng 
>, 
an 
d 
fo 
r 
to 
tal 
nu 
m 
be 
rs 
of 
co 
nfi 
r 
m 
ed 
hu 
an 
ca 
se 
$ 
of 
H 
N 
EFTA_R1_00869443 
EFTA02180185
Vir 
US 
by 
co 
un 
tr 
se 
e 
th 
e 
361 
.11 
Sta 
Ian 
0 
w 
QLAY 
0 ia 
an 
Sit 
CO 
n_ 
ou 
t. 
On 
9 
M 
an 
y 
co 
un 
tri 
es 
in 
thi 
$ 
EFTA_R1_00869444 
EFTA02180186
re 
9' 
on 
ha 
ye 
hi 
gh 
in 
ci 
de 
nc 
e 
ra 
te 
$ 
of 
ILO 
sis 
a 
nd 
hi 
gh 
H
TV 
re 
va 
le 
nc 
e 
ra 
te 
s. 
To 
of 
pa 
ge 
t 
yl 
n 
H 
e 
al 
t 
EFTA_R1_00869445 
EFTA02180187
E. a IS'. • is' (0 CA a.< 
to rD - in ro r, co n n N in 5 rt (i) < -o -o 7 -I 7c 0 -On 7 7C 0`.< 
EFTA02180188
ng 
ar 
e 
sp 
re 
ad 
th 
r0 
ug 
in 
se 
ct 
bit 
es 
0 
ne 
of 
th 
e 
be 
st 
pr 
of 
ec 
do 
ns 
is 
to 
pr 
ev 
en 
t 
in 
se 
ct 
bit 
es 
by 
• 
U 
9 
e 
t 
r 
EFTA_R1_00869447 
EFTA02180189
e 
e 
t 
C 
b 
r e 
h t 
0 
% - 
5 
0 
E 
E 
C D 
r 
V 
a 
e b 
a 
EFTA_R1_00869448 
EFTA02180190
1 
5 
% 
C 
o 
n 
c 
e 
n 
t 
r 
a 
t 
i 
0 
n 
s 
n 
e 
e 
d 
s 
m 
0 
r 
e 
f 
r 
e 
cl 
u 
e 
n 
t 
a 
P 
P 
i 
c 
a 
t 
0 
n 
T 
h 
e 
r 
e 
i 
s 
I 
e 
s 
s 
EFTA_R1_00869449 
EFTA02180191
O 
r 
m n 
0 
n t 
V 
a 
e 
0 
n 
h 
O 
e 
e 
t 
V 
e b 
n r 
r 
0 
t 
e 
t 
n t 
a 
9 
EFTA_R1_00869450 
EFTA02180192
$ 
t n 
t 
h 
e 
t 
e 
0 
m 
0 
t 
0 
e 
t 
h 0 
t 
r t 
$ 
t 
m n 
a 
r 
• 
e 
a 
r 
n 
9 
EFTA_R1_00869451 
EFTA02180193
0 
n 
9-
s 
e 
e 
v 
e 
d 
s 
h 
i 
r 
t 
s 
I 
0 
n 
9 
P 
a 
n 
t 
s 
a 
n 
d 
a 
h 
a 
t 
0 
u 
t 
d 
0 
0 
r 
s 
• 
R 
e 
m 
a 
i 
n 
i 
n 
9 
i 
n 
d 
0 
0 
EFTA_R1_00869452 
EFTA02180194
r 
e 
e 
d 
0 
r e 
r-
t 
0 
e 
d 0 
e 
r 
9 
t 
h 
e 
e d 
14 
9 
e 
r n 
d 
f 
EFTA_R1_00869453 
EFTA02180195
0 
r 
in 
a 
a 
r 
i 
a 
( 
d 
u 
s 
k 
a 
n 
d 
d 
a 
w 
n 
) 
• 
S 
I 
e 
e 
P 
i 
n 
9 
i 
n 
b 
e 
d 
s 
c 
0 
v 
e 
r 
e 
d 
b 
Y 
n 
e 
t 
s 
t 
r 
e 
a 
t 
e 
d 
EFTA_R1_00869454 
EFTA02180196
vi 
I 
t 
Ii 
P 
e 
r 
m 
e 
t 
h 
r 
i 
ri 
i 
f 
n 
0 
t 
s 
e 
e 
P 
I 
n 
9 
i 
n 
a 
n 
a 
i 
r-
c 
0 
n 
d 
i 
t 
i 
0 
n 
e 
d 
0 
r 
w 
e 
I-
s 
C 
r 
e 
e 
n 
e 
EFTA_R1_00869455 
EFTA02180197
d 
r 
0 
0 
m 
• 
S 
P 
r 
a 
Y 
i 
n 
9 
r 
0 
0 
m 
s 
w 
i 
t 
h 
P 
r 
0 
d 
u 
c 
t 
s 
e 
f 
f 
e 
c 
t 
i 
v 
e 
a 
9 
a 
i 
n 
s 
t 
f 
Y 
i 
n 
9 
i 
n 
s 
e 
EFTA_R1_00869456 
EFTA02180198
t 
U 
C 
h C 
t 
h 
0 
e 
C 
0 
t $ 
9 
p 
r 
e 
t 
h 
r 
0 
Fo 
r 
de 
tai 
le 
d 
mf 
or 
m 
ati 
on 
ab 
ou 
t 
in 
se 
Ct 
re 
pe 
Ile 
nt 
EFTA_R1_00869457 
EFTA02180199
PignaWlaS la UR: P IS1° SP 
P 
r 
e 
v 
e 
n 
t 
A 
ni 
m 
al 
Bi 
t 
e 
s 
a 
n 
d 
S 
c 
r 
a 
t 
c 
h 
e 
s 
Di 
re 
ct 
EFTA_R1_00869458 
EFTA02180200
co 
nt 
ac 
t 
wi 
th 
an 
im 
al 
Ca 
sp 
re 
ad 
di 
se 
as 
es 
lik 
e 
ra 
bi 
es 
or 
ca 
us 
e 
se 
no 
us 
inj 
jr 
or 
it 
ne 
ss 
It 
is 
im 
po 
rt 
an 
t 
to 
pr 
ev 
en 
t 
an 
im 
al 
bit 
es 
an 
EFTA_R1_00869459 
EFTA02180201
^ODOC)• • DO '^dD -nnoi<wc mak " CD ^ ^N O. 0 el' C C• C O•< C tn N co • 
m 
Ix 
io0 
0 
EFTA02180202
0 
It 
0 
r 
e 
e t 
n 
m n 
n 
9 
0 
9 $ n 
n 
E 
V 
e 
n t 
m n 
t 
t 
EFTA_R1_00869461 
EFTA02180203
0 
k 
k 
e 
h 
e 0 
h 
e 
t t 
h 
e 
r V 
0 e 
h 
e 
d 
e t 
e 
H 
e 
d 
EFTA_R1_00869462 
EFTA02180204
e 
n 
s 
t 
a 
Y 
s 
a 
f 
e 
b 
Y 
s 
u 
P 
e 
r 
v 
i 
s 
i 
n 
9 
t 
h 
e 
m 
c 
a 
r 
e 
f 
u 
I 
Y 
a 
r 
0 
u 
n 
d 
a 
I 
a 
n 
i 
m 
a 
I 
s 
• 
I 
f 
Y 
0 
EFTA_R1_00869463 
EFTA02180205
u 
a 
r 
e 
b 
t 
t 
e 
n 
0 
r 
s 
c 
r 
a 
t 
c 
h 
e 
d 
w 
a 
s 
h 
t 
h 
e 
w 
0 
u 
n 
d 
w 
e 
I 
w 
i 
t 
h 
s 
0 
a 
P 
a 
n 
d 
w 
a 
t 
e 
r 
a 
n 
d 
9 
EFTA_R1_00869464 
EFTA02180206
0 
t 
0 
a 
d 
0 
c 
t 
0 
r 
r 
i 
9 
h 
t 
a 
w 
a 
Y 
A 
f 
t 
e 
r 
Y 
0 
u 
r 
t 
r 
P 
b 
e 
s 
u 
r 
e 
t 
0 
t 
e 
I 
Y 
0 
u 
r 
d 
0 
c 
t 
0 
r 
EFTA_R1_00869465 
EFTA02180207
0 
r 
s 
t 
a 
t 
e 
h 
e 
a 
t 
h 
d 
e 
P 
a 
r 
t 
m 
e 
n 
t 
i 
f 
Y 
0 
u 
w 
e 
r 
e 
b 
i 
t 
t 
e 
n 
0 
r 
s 
c 
r 
a 
t 
c 
h 
e 
d 
d 
u 
r 
i 
n 
9 
t 
r 
a 
v 
EFTA_R1_00869466 
EFTA02180208
e 
Fo 
r 
n 
or 
e 
inf 
or 
n 
ati 
on 
ab 
ou 
t 
ra 
bu 
es 
an 
d 
tr 
av 
el, 
se 
e m 
e血브亞m明뾰r中아m 
e 
血血且曲姚0 
rC巾Qq立血벼至mmm四 
EFTA Ri 00869467 
EFTA02180209
e. 
Fo 
r 
or 
e 
inf 
or 
au 
on 
ab 
ou 
ho 
w 
to 
pr 
of 
ec 
yo 
ur 
se 
If 
fr 
0 
of 
he 
r 
ris 
ks 
rel 
at 
ed 
to 
an 
im 
al 
5, 
se 
eA 
Di 
m 
ak
ci 
at 
ESL 
Iz
at 
EFTA_R1_00869468 
EFTA02180210
N gt, to 5 ,°1 ri m 0 s,' m ,c4 F a ca' a 3' 3 0 t &I', ,tg 9 rD rr w Eam d ao o m e't C 0 0- ro n co co 
m 
ID
0 8 
EFTA02180211
of 
II 
ne 
ss 
in 
tr 
av 
el 
er 
s. 
Fo 
lb
w 
th 
es 
e 
tip 
$ 
fo 
r 
sa 
fe 
ea 
tin 
9 
an 
Cr 
in 
ki 
ng 
a 
h 
r 
h Il 
n 
0 
t 
e 
n 
w 
t 
h 
EFTA_R1_00869470 
EFTA02180212
0 
a 
P 
a 
n 
d 
w 
a 
t 
e 
r 
e 
s 
P 
e 
c 
i 
a 
I 
I 
Y 
b 
e 
f 
0 
r 
e 
e 
a 
t 
i 
n 
9 
I 
f 
s 
0 
a 
P 
a 
n 
d 
w 
a 
t 
e 
r 
a 
r 
e 
n 
0 
t 
a 
v 
a 
EFTA_R1_00869471 
EFTA02180213
i 
a 
b 
e 
u 
s 
e 
a 
n 
a 
c 
0 
h 
0 
b 
a 
s 
e 
d 
h 
a 
n 
d 
9 
e 
( 
IN 
i 
t 
h 
a 
t 
e 
a 
s 
t 
6 
0 
% 
a 
c 
0 
h 
0 
) 
• 
D 
r 
EFTA_R1_00869472 
EFTA02180214
M CU n M VI rn O. —ao C 17" O.M " CU MO an a fl -I fp er pi a (1) -.0 a-% aft — re. no a —Dor 
m 
Ix 
0 
W 
EFTA02180215
S 
0 
r 
b 
0 
t 
t 
e 
s 
A 
v 
0 
i 
d 
t 
a 
P 
w 
a 
t 
e 
r 
f 
0 
u 
n 
t 
a 
i 
n 
d 
r 
i 
n 
k 
s 
a 
n 
d 
i 
C 
e 
c 
u 
b 
e 
s 
I 
f 
t 
h 
EFTA_R1_00869474 
EFTA02180216
n 
0 
$ 
e 
e t 
n 
h 
0 
w 
t 
0 
m r 
e 
w k 
e 
r 
$ t 
r 
t e 
d 
rl 
k 
D 
0 
t 
e 0 
EFTA_R1_00869475 
EFTA02180217
0 
0 
d 
P 
u 
r 
c 
h 
a 
s 
e 
d 
f 
r 
0 
m 
s 
t 
r 
e 
e 
t 
v 
e 
n 
d 
0 
r 
s 
• 
M 
a 
k 
e 
s 
u 
r 
e 
f 
0 
0 
d 
I 
s 
f 
u 
I 
Y 
c 
0 
0 
k 
e 
d 
EFTA_R1_00869476 
EFTA02180218
A 
v 
0 
i 
d 
d 
a 
i 
r 
Y 
P 
r 
0 
d 
u 
c 
t 
s 
u 
n 
I 
e 
s 
s 
Y 
0 
u 
k 
n 
0 
w 
t 
h 
e 
Y 
h 
a 
v 
e 
b 
e 
e 
n 
P 
a 
s 
t 
e 
u 
r 
i 
z 
e 
d 
Di 
EFTA_R1_00869477 
EFTA02180219
se 
as 
es 
fr 
O 
fo 
od 
an 
d 
yr 
at 
er 
of 
to 
n 
ca 
us 
e 
vo 
mi 
tin 
9 
an 
d 
di 
ar 
rh 
ea 
ak 
e 
su 
re 
to 
br 
in 
9 
di 
ar 
rh 
ea 
m 
ed 
ici 
ne 
wi 
th 
yo 
so 
th 
at 
yo 
Ca 
EFTA_R1_00869478 
EFTA02180220
tr 
ea 
t 
ml 
Id 
ca 
se 
$ 
yo 
Ur 
se 
If. 
A 
V 
of 
d 
In 
ri 
e 
Ca 
r 
cr 
as 
he 
ar 
e 
le 
ad 
in 
9 
ca 
us 
e 
of 
in 
a 
m 
on 
9 
tr 
av 
el 
er 
s. 
Pr 
EFTA_R1_00869479 
EFTA02180221
of 
ec 
yo 
ur 
se 
If 
fr 
0 
m 
th 
es 
e 
inj 
ur 
ie 
$ 
by 
N 
d 
r 
n 
k 
n t 
d 
r 
V 
n 
e n 
r 
n 
9 
y 
0 
r 
EFTA_R1_00869480 
EFTA02180222
e 
a 
t 
b 
e 
t 
a 
n 
d 
u 
s 
i 
n 
9 
c 
a 
r 
s 
e 
a 
t 
s 
0 
r 
b 
0 
0 
s 
t 
e 
r 
s 
e 
a 
t 
s 
n 
t 
h 
e 
b 
a 
c 
k 
s 
e 
a 
t 
f 
0 
r 
c 
h 
i 
I 
d 
r 
EFTA_R1_00869481 
EFTA02180223
n 
• 
F 
0 
0 
n e 
0 
r t 
a 
$ w 
e 
a 
r 
n 
9 
e 
m 
e 
t 
w 
h 
e 
n 
0 
r 
e 
b 
EFTA_R1_00869482 
EFTA02180224
I 
k 
e 
s 
m 
0 
t 
0 
r 
c 
Y 
c 
e 
s 
a 
n 
d 
m 
0 
t 
0 
r 
b 
i 
k 
e 
s 
• 
N 
0 
t 
9 
e 
t 
t 
i 
n 
9 
0 
n 
a 
n 
0 
v 
e 
r 
0 
a 
d 
e 
d 
b 
u 
EFTA_R1_00869483 
EFTA02180225
O 
r 
n 
b 
S 
• 
H 
r 
n S 
0 
V 
e 
r 
w 
h 
e 
n 
O 
S 
$ 
e d 
V 
0 
n 
9 
n 
9 
h A 
EFTA_R1_00869484 
EFTA02180226
t 
d 
r 
i 
v 
i 
n 
9 
0 
t 
h 
e 
r 
H 
e 
al 
t 
h 
Ti 
P 
s 
• 
T 
0 
a 
v 
0 
i 
d 
i 
n 
f 
e 
c 
t 
i 
0 
n 
s 
s 
u 
c 
h 
a 
s 
H 
I 
V 
a 
n 
EFTA_R1_00869485 
EFTA02180227
000nryal^n0 -.01CD-0.000MM -‘0)7M POMOO.M —^—nCil'OM= —Ci.04"—<0. 
m 
ID
O 8 
EFTA02180228
e 
t 
0 
n 
• 
T 
0 
r 
e 
d 
e 
t 
h 
e 
r 
k 
0 
H 
I n 
a 
d 
0 
t 
h 
e 
r 
e 
x n 
r t 
n 
t 
t 
e 
d 
EFTA_R1_00869487 
EFTA02180229
d 
i 
s 
e 
a 
s 
e 
s 
a 
vi 
a 
Y 
s 
u 
s 
e 
a 
t 
e 
x 
c 
0 
n 
d 
0 
m 
s 
• 
T 
0 
P 
r 
e 
v 
e 
n 
t 
f 
u 
n 
9 
a 
a 
n 
d 
P 
a 
r 
a 
s 
i 
t 
i 
C 
EFTA_R1_00869488 
EFTA02180230
n 
f 
e 
c 
t 
i 
0 
n 
s 
, 
k 
e 
e 
P 
f 
e 
e 
t 
c 
e 
a 
n 
a 
n 
d 
d 
r 
Y 
a 
n 
d 
d 
0 
n 
0 
t 
9 
0 
b 
a 
r 
e 
f 
0 
0 
t 
e 
s 
P 
e 
c 
i 
a 
EFTA_R1_00869489 
EFTA02180231
n 
b 
e 0 
e 
w 
h 
e 
r 
e h 
m n 
m 
h 
e 
d 
e 
f 
e V 
e 
of 
Pa 
ge 
A 
ft 
e 
O 
R 
e 
EFTA_R1_00869490 
EFTA02180232
t 
u 
r 
n 
H 
O 
m 
e 
If 
yo 
u 
ar 
e 
no 
t 
fe 
eli 
ng 
w 
eli 
yo 
u 
sh 
ou 
Id 
se 
e 
yo 
ur 
do 
ct 
or 
an 
d 
m 
en 
tio 
n 
th 
at 
yo 
u 
ha 
ye 
re 
ce 
ntl 
y 
tr 
av 
el 
ed 
EFTA_R1_00869491 
EFTA02180233
Al 
so 
tel 
yo 
ur 
do 
ct 
or 
If 
y0 
er 
e 
but 
to 
or 
sc 
ra 
tc 
he 
d 
by 
an 
an 
urn 
al 
w 
hi' 
e 
tr 
av 
eli 
ng 
If 
yo 
ha 
ye 
vi 
sit 
ed 
a 
al 
an 
a-
ris 
k 
ar 
ea 
co 
EFTA_R1_00869492 
EFTA02180234
nu 
nu 
e 
to 
ki 
ng 
yo 
ur 
an 
ti 
m 
al 
ari 
al 
dr 
ug 
fo 
r 
w 
ee 
k$ 
(cl 
ox 
yc 
yc 
lin 
e 
or 
m 
en 
oq 
ui 
ne 
or 
se 
ye 
n 
da 
ys 
(a 
to 
va 
qu 
on 
e/ 
pr 
og 
ua 
nil 
of 
to 
r 
le 
av 
EFTA_R1_00869493 
EFTA02180235
in 
9 
th 
e 
riS 
k 
ar 
ea 
14 
ar 
is 
is 
w 
ay 
a 
se 
ri 
0 
di 
se 
as 
a 
n 
d 
m 
ay 
b 
d 
di 
y 
it 
n 
es 
s. 
If 
yo 
be 
co 
m 
e 
it 
wi 
th 
a 
EFTA_R1_00869494 
EFTA02180236
fe 
ye 
or 
flu-
lik 
e 
it 
ne 
ss 
elt 
he 
w 
hil 
e 
tr 
av 
ell 
ng 
in 
a 
m 
al 
ari 
a-
ris 
k 
ar 
ea 
or 
of 
to 
yo 
re 
to 
rn 
ho 
m 
e 
(f 
or 
up 
to 
1 
ye 
ar 
), 
yo 
sh 
ou 
Id 
se 
ek 
EFTA_R1_00869495 
EFTA02180237
m 
m 
di 
at 
ed 
IC 
al 
at 
to 
nti 
on 
an 
d 
sh 
ou 
Id 
tel 
th 
e 
ph 
ys 
ICI 
an 
yo 
ur 
tr 
av 
el 
hi 
st 
Or 
iP
it 
N 
dl 
u 
EFTA_R1_00Et69496 
EFTA02180238
Is 
In 
EFTA_R1_00869497 
EFTA02180239
at 
io 
n 
re' 
la 
to 
d 
Y 
0 
ur 
n 
io 
n 
er, 
fo' 
r 
pr 
nt 
0 w 
EFTA_R1_00889498 
EFTA02180240
To 
2 
of 
Pa 
ta 
M 
a 
P 
DI 
Sc 
Ia 
I 
m 
EFTA_R1_00Et69499 
EFTA02180241
er 
Th 
e 
bo 
un 
da 
rie 
$ 
an 
na 
es 
sh 
0 
w 
n 
an 
th 
e 
de 
si 
gn 
ati 
on 
us 
ed 
on 
m 
ap 
do 
no 
t 
im 
pl 
th 
ex 
pr 
es 
Si 
on 
of 
an 
op 
ini 
on 
w 
ha 
is 
oe 
EFTA_R1_00869500 
EFTA02180242
ve 
r 
on 
th 
e 
pa 
rt 
of 
th 
e 
Ce 
nt 
er 
fo 
r 
Di 
se 
as 
Co 
nt 
rol 
an 
d 
Pr 
eV 
en 
do 
n 
co 
nc 
er 
ni 
ng 
th 
e 
It 
ga 
st 
at 
us 
of 
an 
co 
un 
tr 
Y. 
to 
rri 
to 
FY 
Cit 
EFTA_R1_00869501 
EFTA02180243
or 
ar 
ea 
or 
of 
its 
au 
th 
on 
tie 
s, 
or 
co 
nc 
er 
ni 
ng 
th 
de 
li 
mi 
to 
do 
of 
its 
fr 
on 
tie 
rs 
or 
bo 
un 
da 
rie 
s. 
A 
pp 
ro 
xi 
m 
at 
bo 
rd 
er 
lin 
es 
fo 
r 
w 
hi 
Cl, 
th 
er 
e 
EFTA_R1_00869502 
EFTA02180244
ay 
no 
t 
ye 
t 
be 
fu! 
.39 
re 
e 
m 
en 
t 
ar 
e 
ge 
ne 
ral 
ly 
ar 
ke 
d. 
Text size: 
M 
XL 
Email page 
Print page 
Bookmark and share 
Add this to... 
Favorites 
Deticio.L45
Digg 
Face book 
Google Bookmarks 
Yahoo MyWeb 
Get email updates 
Contact Us: 
Centers for Disease Control and Prevention 
1600 Clifton Rd 
Atlanta, GA 30333 
800-CDC-INFO 
(900-232.4636) 
TTY: (888) 232-6348 
New Hours of Operation 
8am-8pm ET/Monday-Friday 
Closed Holidays 
g_d_chtfolvspc.gcw 
Email page 
Print page 
Bookmark and share 
EFTA_R1_00869503 
EFTA02180245
Add this to... 
Favorites 
Digg 
Facebook 
Google Bookmarks 
Yahoo MyWeb 
Get email updates 
Page created: February 22, 2011 
Page last updated: November 03, 
2011 
Page last reviewed: September 29, 
2011 
Content source: Centers for 
Disease Control and Prevention 
National Center for Emerging and Zoonotic Infectious 
Diseases (NCEZIO) 
Division of Global Migration and 
Quarantine (DGMQ) 
Travelers' HealthAll CDC Topics 
Search The CDC Search Button 
On Nov 9, 2011, at 2:53 PM, Jeffrey Epstein wrote: 
find out about disease shots for ivory coast. 
rasseck tells me malaria is there 
** 
The information contained in this communication is 
confidential, may be attorney-client privileged, may 
constitute inside information, and is intended only for 
the use of the addressee. It is the property of 
Jeffrey Epstein 
Unauthorized use, disclosure or copying of this 
communication or any part thereof is strictly prohibited 
and may be unlawful. If you have received this 
communication in error, please notify us immediately by 
return c-mail or by e-mail to kevacationftamail com, and 
destroy this communication and all copies thereof, 
including all attachments. copyright -all rights reserved 
EFTA_R1_00869504 
EFTA02180246



=== IMAGE DESCRIPTIONS ===
[Image 1] The image appears to be a document scan, possibly a letter or a report, with text and a table. The visible text includes a heading, a paragraph, and a list of items or points. The table has columns with headings and rows with text. The document contains a date and a name, but the specific details are not clear due to the resolution and quality of the image.

[Image 2] The image appears to be a photograph of a printed document, possibly a form or a letter. The document contains text fields with headings such as "Name," "Address," "City," "State," "Zip Code," "Phone Number," and "Email Address." There is also a section titled "Reason for Contact" with a checkbox next to it. Below this, there is a paragraph of text that seems to be a message or a letter. The text 

[Image 3] The image appears to be a document, possibly a table or a list, with text content. The text is too small to read clearly, and the document is rotated, making it difficult to provide a detailed description. The document seems to contain a series of items or points, but without a clearer view or a higher resolution image, it's not possible to provide a more detailed description.

[Image 4] The image shows a document with text, which appears to be a page from a report or a formal document. The text is too small to read clearly, but it seems to be structured with headings, subheadings, and paragraphs. There are no visible names, dates, places, or logos that can be discerned from this image. The document is presented in a portrait orientation, and the background is not visible due to t

[Image 5] The image appears to be a scanned document, possibly a letter or a report. It contains text with headings and paragraphs, but the content is not clearly visible due to the resolution and angle of the scan. The document has a header with a date and a footer with a page number. There are no visible names, logos, or other identifiable features that would allow for a more detailed description.

[Image 6] The image shows a document with text, which appears to be a printed email or message. The text is partially obscured by a black rectangle, which seems to be a censorship mark. The visible text includes a date, a recipient's name, and a subject line. The date is not fully visible, but it appears to be in the month of September. The recipient's name is partially obscured, but it seems to start with